These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2008-008794-55 A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma 2014-02-15 due-trials
Reported results Terminated 2012-000542-35 Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases. 2018-07-25 due-trials
Ongoing 2012-004895-21 Phase II randomised placebo controlled NEOadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive BLADder cancEr not-yet-due
Ongoing 2014-002382-30 Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer: not-yet-due
Ongoing 2014-004653-14 A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patient with metastatic pancreatic carcinoma. (ACELARATE) not-yet-due
Ongoing 2016-004215-13 Randomised Phase II Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical Cancer (COMICE) not-yet-due
Ongoing 2017-005015-13 NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer not-yet-due
Ongoing 2018-000004-42 TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC not-yet-due
Ongoing 2019-000842-36 A Polatuzumab Vedotin Containing Chemo-Immunotherapeutic Regimen in Patients with Diffuse Large B-Cell Lymphoma Unsuitable for Full Dose R-CHOP Therapy not-yet-due